HOUSTON–(February 20, 2024)–Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, has been named to its Board of Directors.

“Dr. Lammers’ success in leading both private and public biopharma companies, combined with his extensive experience in fundraising, will provide critical experience in guiding our clinical development and commercialization of Diakonos’ unique cancer immunotherapies,” said Mike Wicks, Chief Executive Officer of Diakonos. “His pivotal role in advancing cell therapies for cancer perfectly aligns with our mission to revolutionize the treatment landscape for patients facing the most challenging cancers.”

Dr. Lammers is recognized for his strategic leadership and successful fundraising efforts, notably as President and CEO of Triumvira Immunologics, where he raised substantial venture funding focusing on CAR T-cell therapies for solid tumors. Before Triumvira, he led Mirna Therapeutics as President and CEO, taking the company public on NASDAQ in 2015. His earlier roles include Chief Medical Officer and Head of US Product Development at EMD Serono, where he oversaw a large team of professionals, and various executive positions that showcased his expertise in clinical development, medical, and regulatory affairs across the pharmaceutical and biotech sectors.

“I am deeply honored to join the Diakonos team and contribute to their groundbreaking work in developing dendritic cell vaccines. This technology represents a significant leap forward in cancer treatment, promising a new era of personalized and effective immunotherapies for patients in dire need,”  Dr. Lammers said.

About Diakonos Oncology Corp.

Based out of Houston, TX, Diakonos Oncology is at the forefront of developing dendritic cell vaccines that leverage a patient’s immune system to target and eliminate cancer cells, mimicking the body’s natural response to viral infections. Initiating a natural immune response without any genetic modification of the patient’s immune cells, Diakonos has seen both encouraging efficacy and safety in its clinical trials to date.

With its leading candidate, DOC1021, Diakonos recently completed its Phase 1 trial for glioblastoma (NCT04552886) at MD Anderson Cooper and UTHealth Houston. Diakonos is underway with additional trials for pancreatic cancer at Baylor College of Medicine (NCT04157127) and angiosarcoma at MD Anderson (NCT05799612).


Jay Hartenbach